Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Queensland Health
Argus Health
Cantor Fitzgerald
Federal Trade Commission
QuintilesIMS
Accenture
Covington
AstraZeneca

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,022,095

« Back to Dashboard

Which drugs does patent 8,022,095 protect, and when does it expire?

Patent 8,022,095 protects TREXIMET and is included in one NDA.

Protection for TREXIMET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in eleven countries.
Summary for Patent: 8,022,095
Title:Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Abstract: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1.sub.B/1.sub.D agonist.
Inventor(s): Plachetka; John R. (Chapel Hill, NC)
Assignee: Pozen, Inc. (Chapel Hill, NC)
Application Number:10/414,493
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,022,095
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,022,095

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pernix Ireland Ltd TREXIMET naproxen sodium; sumatriptan succinate TABLET;ORAL 021926-001 Apr 15, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,022,095

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,872,145 Formulation of 5-HT agonist and NSAID for treatment of migraine ➤ Try a Free Trial
6,586,458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs ➤ Try a Free Trial
6,060,499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,022,095

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 957914 ➤ Try a Free Trial
Japan 2005325143 ➤ Try a Free Trial
Japan 2002255855 ➤ Try a Free Trial
Japan 3712420 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Federal Trade Commission
Dow
McKesson
Fish and Richardson
Queensland Health
Cipla
Merck
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.